![Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b00109/asset/images/medium/jm-2017-00109c_0010.gif)
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
![Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects](https://www.mdpi.com/molecules/molecules-28-00346/article_deploy/html/images/molecules-28-00346-g001.png)
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold | ACS Chemical Neuroscience
![Nalfurafine, a G-Protein–Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics | Hypertension Nalfurafine, a G-Protein–Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics | Hypertension](https://www.ahajournals.org/cms/asset/89dcd157-b34a-40c1-b8f1-fd1ddd994952/hypertensionaha.121.18503.fig07.jpg)
Nalfurafine, a G-Protein–Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics | Hypertension
![A Systematic Review on the Kappa Opioid Receptor and Its Ligands: New Directions for the Treatment of Pain, Anxiety, Depression, and Drug Abuse | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage A Systematic Review on the Kappa Opioid Receptor and Its Ligands: New Directions for the Treatment of Pain, Anxiety, Depression, and Drug Abuse | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage](https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/62c8920a6383266dc946ad00/largeThumb/a-systematic-review-on-the-kappa-opioid-receptor-and-its-ligands-new-directions-for-the-treatment-of-pain-anxiety-depression-and-drug-abuse.jpg)
A Systematic Review on the Kappa Opioid Receptor and Its Ligands: New Directions for the Treatment of Pain, Anxiety, Depression, and Drug Abuse | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage
![Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-B978012420118700010X-f10-01-9780124201187.jpg)
Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g001.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g002.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Mu and delta, but not kappa, opioid agonists induce spastic paraparesis after a short period of spinal cord ischaemia in rats† - British Journal of Anaesthesia Mu and delta, but not kappa, opioid agonists induce spastic paraparesis after a short period of spinal cord ischaemia in rats† - British Journal of Anaesthesia](https://www.bjanaesthesia.org.uk/cms/attachment/2107590971/2082057156/gr1.jpg)
Mu and delta, but not kappa, opioid agonists induce spastic paraparesis after a short period of spinal cord ischaemia in rats† - British Journal of Anaesthesia
![Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy | ACS Chemical Neuroscience Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy | ACS Chemical Neuroscience](https://pubs.acs.org/cms/10.1021/cn200128x/asset/images/large/cn-2011-00128x_0006.jpeg)
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy | ACS Chemical Neuroscience
![Structure–activity relationship investigation of triazole-based kappa opioid receptor agonists | SpringerLink Structure–activity relationship investigation of triazole-based kappa opioid receptor agonists | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00044-021-02746-1/MediaObjects/44_2021_2746_Figa_HTML.png)
Structure–activity relationship investigation of triazole-based kappa opioid receptor agonists | SpringerLink
![Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-88118-6/MediaObjects/41598_2021_88118_Fig7_HTML.png)
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
![Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience](https://pubs.acs.org/cms/10.1021/acschemneuro.9b00195/asset/images/medium/cn-2019-00195v_0008.gif)
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/asset/35d59cc9-5e24-4990-b0eb-4fc248e3274c/9_ra117_f1.gif)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/images/valenza_zamarripa_promo.jpg)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0031942217300420-fx1.jpg)